by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract INTRODUCTION Quantification approaches based on group-level regions of interest (ROIs) are widely used for evaluating tau positron emission tomography (PET) and clinical progression in Alzheimer’s disease (AD), but we hypothesize that personalized...
by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract INTRODUCTION Late-life depression is associated with cognitive impairment, but the underlying neural basis remains to be elucidated. We investigated the role of Alzheimer’s disease (AD)–related plasma biomarkers in the depression–cognition association....
by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract Increasing evidence suggests that myelin dysfunction and oligodendrocyte pathology are active contributors to neurodegeneration. In Alzheimer’s disease (AD), the link between tau aggregation and myelin integrity remains unclear, despite the preferential...
by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia
Abstract Mild cognitive impairment and dementia are underrecognized in primary care, contributing to delayed diagnosis and limited access to care. Growing research has focused on improving cognitive evaluation in primary care, including the development of digital...
by Clinical Neuropsychologist Online | Tuesday, August 18, 2026 | Dementia
Abstract INTRODUCTION Neuroimaging studies report associations of amyloid beta (Aβ) positron emission tomography (PET) with [18F](S)-(2-methylpyrid-5-yl)-6-[(3-fluoro-2-hydroxy)propoxy]quinoline ([18F]SMBT-1), a novel reactive astrogliosis surrogate radiotracer with...
